<DOC>
	<DOCNO>NCT01833611</DOCNO>
	<brief_summary>Entecavir ( ETV ) show superior ability suppress hepatitis B virus ( HBV ) replication , histology improvement well low rate emergence resistant mutant . Out range clinical recommendation treatment chronic hepatitis B ( CHB ) , chronic HBV carrier persistently normal ALT viral load 10^5 copies/mL progression liver disease long-term follow-up . In addition , certain proportion patient significant inflammation fibrosis liver histology . This study able identify risk liver disease progression evaluate efficacy ETV regard improvement liver histology short-term ( 1-year ) long-term ETV treatment ( 3-year ) .</brief_summary>
	<brief_title>Entecavir Chronic Hepatitis B Patients With Persistently Normal ALT</brief_title>
	<detailed_description>TITLE : A Randomized , Double-blind , Placebo-control Study Evaluating Efficacy Entecavir Patients Chronic Hepatitis B Virus Infection Persistently Normal Alanine Aminotransferase INDICATION : Chronic hepatitis B virus infection persistently normal ALT OBJECTIVES : Primary objective To evaluate efficacy entecavir ( ETV ) improve liver histology patient chronic hepatitis B virus infection persistently normal ALT . The primary endpoint compare proportion subject treatment group achieve histologic Endpoint , define improvement necroinflammatory score ( ≥ 2 point decrease Knodell HAI score ) worsen fibrosis ( ≥ 1 point increase Knodell fibrosis score ) , Week 52 compare baseline . Secondary objective To compare proportion subject treatment group follow objective week 52 , week 104 , week 156 , post-dosing 24 week : 1 . Undetectable HBV DNA Roche TaqMan® HBV Test ( limit detection 60 IU/mL ) ; HBV DNA PCR also evaluate continuous parameter ; 2 . The reduction HBV DNA baseline . STUDY DESIGN This 3-year prospective randomize , double-blind , placebo-control study . Enrolled subject allocate accord HBeAg status ( HBeAg-positive HBeAg-negative ) , randomize ETV placebo group . ETV group : 1st year : ETV 0.5mg qd , open ETV 0.5mg qd 2nd , 3rd year Placebo gr : 1st year : placebo , open ETV 0.5mg 2nd , 3rd year Dose ETV : 0.5 mg/day Screening period : 6 week Timing liver biopsy : baseline , 52th week , 156th week NUMBER OF PATIENTS 130 ( 1:1 ) STUDY PERIOD NOV 2007 ~ MAY 2011 DRUG ADMINISTRAITON Route : oral Dose : ETV 0.5 mg/day Comparable placebo STATISTICAL ANALYSIS Sample size determination : An evaluation efficacy entecavir compare placebo plan . A test superiority entecavir placebo conduct high power demonstrate superiority large histologic improvement clinical importance . Histologic improvement one year estimate 50 % entecavir treatment 25 % placebo . Thus , sample size 47 require 90 % confidence level 5 % error . Finally , estimate appropriate enroll 65 patient arm due probably patient ' withdrawal . Statistical Analyses The difference response rate Histologic Endpoint ( entecavir-placebo ) along standard error 95 % confidence interval compute . Subset analysis define prognostic variable [ e.g . gender , HBV DNA level ] Histologic Endpoint perform . Change baseline Week 52 156 Knodell Scores also summarize continuous parameter . The secondary efficacy variable also summarize compare treatment group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Male female subject age 18 65 yearold history chronic hepatitis B virus infection ; 2 . Detectable HBsAg screen least 24 week prior screen detectable HBsAg &lt; 24 week negative IgM core antibody confirmation chronic hepatitis liver biopsy ; 3 . ALT within normal range recent one year least twice , least 3 month apart ; 4 . Normal ALT screening ; 5 . Screening HBV DNA 10^5 copies/mL Roche AmplicorTM PCR assay performed central laboratory ; 6 . Evidence chronic hepatitis liver biopsy ( Knodell HAI Score &gt; = 4 ) perform ≤ 52 week prior randomization ; 7 . All woman childbearing potential must negative serum urine pregnancy test . 1 . Coinfection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) ; 2 . Other form liver disease e.g. , alcoholic , autoimmune , biliary disease ; 3 . Patients evidence decompensation liver disease ; 4 . Therapy interferon , thymosin alpha antiviral agent activity hepatitis B ( e.g. , adefovir , famciclovir , lamivudine , telbivudine ) within 24 week randomization study ; 5 . More 12 week prior therapy nucleoside nucleotide analogue antiviral agent activity hepatitis B ( e.g. , adefovir , famciclovir lamivudine , telbivudine ) ; 6 . Prior therapy entecavir ; 7 . Known history allergy nucleoside analogue ; 8 . Hemoglobin &lt; 10.0 g/dL ; 9 . Platelet count &lt; 75,000/mm3 ; 10 . Absolute neutrophil count &lt; 1500 cells/mm3 ; 11 . Creatinine &gt; 1.5mg/dL ( 133 μmol/L ) ; 12 . Antinuclear antibody ( ANA ) titer &gt; l :160 unless attributable nonhepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>